EU regulators develop recommendations to forecast demand of medicines

4 June 2021
ema_building-credit_rob_acket

The EU Executive Steering Group on Shortages of Medicines Caused by Major Events has adopted a reflection paper which contains recommendations to support forecasting of demand for human medicinal products across the European Union (EU) and also at the national level in exceptional situations like the COVID-19 pandemic, whenever such activity is undertaken, the European Medicines Agency announced.

A global health emergency, such as the COVID-19 pandemic, can drive a sudden surge in demand for certain medicines used to treat patients. The document builds on the experience gained by EU authorities last year, during the first wave of the pandemic, and presents a common methodology to predict the demand of medicines for use in intensive care units (ICUs).

The methodology is based on pragmatic predictions of demand for certain medicines and encourages the use of the best available information, with an aim to reach the right balance between existing uncertainties with regards to the actual future demand, and the imperative public health need to prepare for a potential major increase in demand.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical